The Quick Version
- The gap between incurring R&D spend and receiving your rebate (your company tax rate plus an 18.5% premium, which works out to 43.5% for most eligible SMEs) can stretch beyond 15 months, and tighter ATO compliance activity in 2025-26 is making that timeline less predictable.
- During that waiting period, your burn rate for startup metrics looks artificially high because the cash hasn’t landed, even though the rebate is legitimate and confirmed.
- A distorted Burn Multiple (the metric VCs use to assess capital efficiency) can shift investor perception of your company from “efficient” to “suspect” based purely on timing.
- Compressed runway forces founders into reactive fundraising, often at weaker valuations, or pushes them toward equity rounds that cost 20-35% annualised versus ~16% for short-term R&D debt.
- R&D finance lets you borrow against eligible spend you’ve already incurred, bridging the gap without monthly repayments, personal guarantees, or dilution.
You’ve spent $2 million on R&D this financial year. Your R&D Tax Incentive claim will return $870,000 at the refundable offset (your 25% company tax rate plus the 18.5% R&D premium, totalling 43.5% for most eligible companies under $20M turnover), and that number is probably sitting in your financial model right now, labelled something like “R&DTI receivable” or “expected government rebate.” It feels solid. It is solid. If you’ve incurred eligible spend and your R&D tax consultant has confirmed it, the rebate is real.
But certainty of amount is very different from certainty of timing, and timing is where the damage happens. That $870,000 could take well over a year to reach your bank account, and in the meantime, your cash position, your burn rate, and the story your metrics tell to investors are all quietly distorted by the wait.
The 15-Month Cash Trap
The R&DTI operates on a strictly retrospective timeline. You spend on R&D throughout the financial year (July to June), wait for the year to close, then have ten months to register your activities with the Department of Industry, Science and Resources. Business.gov.au confirms that registrations submitted within six months of the year-end are typically processed in 20 business days, but if lodged closer to the April 30 deadline, processing can blow out to 80 business days. After registration, you still need to lodge your company tax return incorporating the R&D schedule, and only after the ATO finalises your assessment does the refund actually hit your account.
For expenditure incurred at the start of the financial year in July, that money might not come back until September or October of the following year. Fifteen months of your capital sitting in regulatory limbo, doing nothing for your operations, your hiring, or your product roadmap. For any founder tracking burn rate for startups at board level, that’s over a year of distortion baked into every financial report.
And that’s the optimistic scenario. The ATO has flagged R&D claims as a key compliance focus for 2025-26, targeting what it describes as incorrect or overclaimed deductions and intermediaries who encourage high-risk tax positions. RSM Australia reports increased audit activity on claims involving large refunds, and DISR introduced a stricter assessment approach in 2025 where assessors can reject an entire registration if a single eligibility requirement isn’t met, without reviewing the rest of the claim. If your claim gets queried, add months to that timeline.
How a Delayed Rebate Inflates Your Burn Rate
This is where the timing gap stops being an accounting inconvenience and starts directly inflating the burn rate for startups carrying an unpaid R&DTI receivable.
The Burn Multiple, a metric coined by David Sacks at Craft Ventures, has become one of the most scrutinised efficiency measures in venture capital. It calculates how much cash you burn to generate each dollar of new annual recurring revenue (ARR), expressed as Net Burn divided by Net New ARR. AirTree Ventures, one of Australia’s most active early-stage VCs, calls it their preferred metric for assessing growth efficiency, and the benchmarks are tight: under 1x is exceptional, between 1x and 1.5x is great, and anything pushing above 2x starts triggering serious due diligence concerns.
The delayed receipt of the R&DTI distorts this calculation in a way that’s almost invisible unless you know to look for it. Consider a startup generating $2 million in net new ARR over 12 months, with $4 million in total operating expenses, half of which is eligible R&D. The company is owed an $870,000 rebate.
If that rebate arrived in real time, net burn would be $3.13 million, and the Burn Multiple would sit at 1.56x, comfortably within the range investors want to see. But the rebate hasn’t arrived. It’s trapped in the ATO pipeline. So the actual cash burn stays at $4 million, and the Burn Multiple jumps to 2.0x, right into the territory that makes investors question whether your unit economics are broken.
Same company, same ARR growth, same team. The only variable is whether the government has processed the paperwork yet.
Runway Shrinks, Milestones Slip
When the burn rate for startups appears higher than it should, the natural consequence is that the runway looks shorter than it is. And short runways force bad decisions.
A well-capitalised startup can run product development and commercialisation in parallel: engineering builds the product while sales and marketing warm up the pipeline, so you launch into existing demand rather than starting from zero. But when hundreds of thousands of expected cash is stuck in processing, that parallel model collapses. You can’t fund the marketing push until the technical phase finishes and the rebate clears. Product launches get pushed back. Strategic hires get paused. The next funding milestone drifts further out of reach.
For SaaS companies, the cost shows up as lost ARR. Delay a premium product tier by six months because you’re waiting on a rebate to fund backend infrastructure, and you permanently lose six months of enterprise subscription revenue that no amount of catch-up can recover. For biotech firms running clinical trials, a paused Phase II trial still burns capital on lab space and staff retention while destroying the investor confidence needed to secure the next round.
This matters more right now than it has in years. Australian startups raised $5.48 billion across just 390 deals in 2025, a 31% increase in capital flowing to 20% fewer companies. The top 20 deals captured 58% of all funding. Investors are concentrating bets on companies that demonstrate clear capital efficiency, and anything that artificially weakens your metrics is a liability you can’t afford.
What Investors Actually See
Put yourself on the other side of the table for a moment. A founder walks into a pitch with three months of cash runway showing in the bank. There’s a $900,000 ATO receivable on the balance sheet, but it hasn’t cleared AusIndustry yet, and compliance scrutiny is the highest it’s been in years.
The investor sees risk. Not potential. Not a timing anomaly. Risk. Three months of cash, a burn rate for startups that looks unsustainable on paper, and a government receivable that may or may not arrive on schedule. Instead of raising capital to accelerate growth, that founder is raising survival capital, and VCs know the difference. They price it accordingly, with tighter valuations, heavier liquidation preferences, or a down round. PitchBook data shows that nearly 30% of global VC deals in the first half of 2024 were flat or down rounds, and that pressure hasn’t eased.
The cost of equity for early-stage startups typically ranges between 20% and 35% annualised, reflecting the returns VCs need across their portfolio to make the maths work. Selling permanent shares to cover a temporary 12-to-15 month cash flow gap caused by a government processing delay is one of the most expensive capital allocation mistakes a founder can make, and increasingly, sophisticated investors view it as a sign of poor financial planning rather than market necessity.
How R&D Finance Bridges the Gap
This is where Rocking Horse Group comes in, and if you haven’t heard of us before, here’s the short version: we’re a specialist R&D finance lender based in Sydney, serving businesses Australia-wide. We do one thing, and we do it well. We lend against the eligible R&D expenditure your business has already incurred, so you can access the cash value of your R&DTI rebate months before the ATO processes it.
The way it works is simple. Instead of waiting for your refund to clear the multi-agency pipeline described above, you borrow against the spend that’s already happened. When the ATO pays out, the loan is settled in a single bullet payment. No monthly repayments in the meantime, no personal guarantees, and no changes to your cap table.
We provide R&D financing from $50K to $5M, up to 80% of your accrued year-to-date eligible R&D spend, and funding typically lands within two weeks of approval. There are no restrictions on how you use the funds, whether that’s continuing R&D, hiring, marketing, or keeping operations running smoothly while you scale.
What sets us apart
A few things that set us apart from traditional lending. We don’t require personal guarantees, which means founders aren’t putting their homes on the line. We don’t take equity, so your cap table stays clean. And critically, we’re not an R&D tax advisor or consultant. We don’t assess your R&DTI eligibility or lodge claims. That’s your R&D advisor’s role, and you’ll need a comfort letter from one confirming your eligible expenditure before we can proceed. If you don’t have an R&D advisor yet, we can connect you with a trusted one in our network.
The cost of bridging vs. the cost of waiting
The maths is worth spelling out. If you access $870,000 six months early at around 16% per annum, the interest cost sits somewhere around $70,000. Compare that to giving up 5-10% of your company in a rushed equity round at a compressed valuation, and the case for debt financing over equity becomes hard to argue against.
For businesses with R&D programs spanning multiple financial years, our three-year Multi-Facility Agreement keeps your rate 1% lower than the standard single-year rate, with lower exit fees too. Whether you’re a startup building your first product or a growing business scaling across multiple R&D cycles, the facility is structured to grow alongside you.
The strategic benefit goes beyond cost savings. When your R&DTI cash arrives in real time, the burn rate for startups using this approach drops back to reflect how the business actually operates. Your Burn Multiple drops back to where it should be. Your runway extends. And when you do raise equity, you negotiate from a position of strength rather than desperation.
Stop Modelling the Rebate Without Modelling the Wait
The R&D Tax Incentive is one of the most generous innovation incentives globally. But treating it as cash-in-hand before the ATO has processed it creates a blind spot in your financial planning that costs real money, real time, and real equity.
If your business has already incurred eligible R&D spend and plans to lodge an R&DTI claim, there’s no reason to let the timing gap eat into your burn rate, compress your runway, or weaken your position with investors. Check your R&D financing eligibility or use our calculator to see how much you could access today.
You’ve already earned the rebate. We help you use it when it matters most.
FAQs
How long does it typically take to receive an R&DTI refund?
It depends on when your eligible R&D expenditure was incurred and when you lodge your registration. For spending incurred at the start of the financial year in July, the gap between outlay and cash receipts can stretch beyond 15 months. AusIndustry processing alone takes between 20 and 80 business days, depending on how close to the April 30 deadline you submit, and ATO processing of your tax return adds further time on top.
Does a delayed R&DTI refund actually affect my startup’s valuation?
It can, and in ways that aren’t immediately obvious. Investors evaluate companies using cash-based metrics like the Burn Multiple and remaining runway. If your R&DTI rebate hasn’t arrived, your net burn appears higher than your true run-rate, and your cash runway looks shorter. Both of those factors work against you in fundraising negotiations, potentially leading to lower valuations, less favourable terms, or the kind of compressed timeline that forces a down round.
What is R&D finance, and how does it work?
R&D finance is a short-term loan secured against the R&D Tax Incentive rebate you’re entitled to, based on eligible R&D expenditure you’ve already incurred. The loan is repaid when the ATO processes your refund. There are no monthly repayments, no personal guarantees, and no restrictions on how you use the funds. It’s designed to bridge the timing gap between spending on R&D and receiving your government rebate.
Do I need to have completed my R&DTI claim before applying for R&D finance?
No. You can access R&D finance before completing your R&DTI application, though you will need to complete it eventually as part of the normal tax lodgment process. You’ll also need a comfort letter from an R&D tax consultant confirming your eligible expenditure. The lender does not assess R&DTI eligibility or lodge claims. That’s your R&D advisor’s role, and if you don’t have one, most specialist R&D lenders can introduce you to a trusted advisor in their network.
How is R&D finance different from venture debt or a bank loan?
Traditional bank loans typically require positive cash flow, tangible assets, and personal guarantees, which many R&D-heavy startups simply don’t have. Venture debt usually requires a recent equity round and may include warrants that dilute ownership. R&D finance is secured solely against your accrued ATO receivable, involves no personal guarantees or equity dilution, and is settled in a single payment when your rebate arrives.